Catalent (NYSE:CTLT) Shares Gap Up to $54.82

Catalent, Inc. (NYSE:CTLT) shares gapped up prior to trading on Friday . The stock had previously closed at $54.82, but opened at $56.69. Catalent shares last traded at $56.42, with a volume of 1,102,580 shares changing hands.

Analyst Ratings Changes

CTLT has been the topic of several recent research reports. Stephens reissued an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. StockNews.com initiated coverage on Catalent in a research note on Saturday. They issued a “sell” rating on the stock. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $54.05.

Catalent Trading Up 3.1 %

The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77. The firm has a market cap of $10.23 billion, a price-to-earnings ratio of -9.26, a P/E/G ratio of 6.59 and a beta of 1.20. The business has a 50-day moving average of $55.51 and a 200-day moving average of $53.20.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.11 billion. Research analysts anticipate that Catalent, Inc. will post 0.28 EPS for the current year.

Insider Transactions at Catalent

In related news, insider Ricky Hopson sold 1,401 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the completion of the sale, the insider now directly owns 20,617 shares in the company, valued at $1,118,678.42. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

Several institutional investors have recently made changes to their positions in the stock. Lindbrook Capital LLC boosted its stake in shares of Catalent by 79.4% in the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after buying an additional 208 shares during the period. Czech National Bank raised its position in Catalent by 0.7% during the first quarter. Czech National Bank now owns 31,801 shares of the company’s stock valued at $1,795,000 after purchasing an additional 228 shares in the last quarter. BNP Paribas Asset Management Holding S.A. raised its position in Catalent by 1.9% during the fourth quarter. BNP Paribas Asset Management Holding S.A. now owns 17,850 shares of the company’s stock valued at $802,000 after purchasing an additional 328 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. raised its position in Catalent by 6.2% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,703 shares of the company’s stock valued at $256,000 after purchasing an additional 331 shares in the last quarter. Finally, Arizona State Retirement System raised its position in Catalent by 0.7% during the fourth quarter. Arizona State Retirement System now owns 49,546 shares of the company’s stock valued at $2,226,000 after purchasing an additional 365 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.